NN 9925

Drug Profile

NN 9925

Alternative Names: NN9925

Latest Information Update: 12 Nov 2013

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 12 Nov 2013 Discontinued - Phase-I for Type-2 diabetes mellitus in United Kingdom (IV)
  • 12 Nov 2013 Discontinued - Phase-I for Type-2 diabetes mellitus in United Kingdom (PO)
  • 27 Aug 2010 Novo Nordisk completes enrolment in a phase I trial (NCT01087645) in the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top